The presence of high‐level CNVs was investigated, and confirmed the presence of HER2 amplification in all HER2‐positive carcinoma samples, which served as an internal quality control (Figs 1 and 2; Figs S1 and S2). This evidence concerns the gene ERBB2 and carcinoma.